Arkolith/Insider Trading/RARE/Form 4

Suliman Shehnaaz

DirectorUltragenyx Pharmaceutical Inc. (RARE) · full profile →Form 4 · filed May 18, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$144K
Net Open-Market Flow
-$144K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 18, 2026Sell(S)6K$25.12$144K28K
May 14, 2026Grant(A)8K—$034K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 14, 2026Grant(A)14K—$014K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001713070-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML